Substituted bicyclic compounds

Patent metadata

Field	Value
Publication number	US-9770459-B2
Application number	US-201615337843-A
Country	US
Kind code	B2
Filing date	Oct 28, 2016
Priority date	Aug 20, 2014
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

and/or a salt thereof, wherein R 1 is —OH or —OP(O)(OH) 2 , and X 1 , X 2 , X 3 , R 2 , R 2a , R a , R b , and R c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

First claim

What is claimed is:

1. A method for treating an autoimmune disease or a chronic inflammatory disease, comprising administering to a mammalian patient a compound, wherein said autoimmune disease and chronic inflammatory disease is selected from systemic lupus erythematosis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, scleroderma, giant cell arteritis, and Sjogren's syndrome, wherein said compound is

or salt there of; wherein R 1 is —OH or —OP(O)(OH) 2 .
R 2 is R 2a or R 2b ;
represents either a single bond to R 2a or a double bond to R 2b ;
R 2a is —(CH 2 ) 3-6 CH 3 , —(CH 2 ) 1-4 CH═CR x R x , —(CH 2 ) 1-4 CH═CR x (CH 2 CH 3 , —CH═CH(CH 2 ) 1-3 C(R x ) 3 , —CH═CH(CH 2 ) 1-3 OCH 3 , —(CH 2 ) 1-3 CH═CHCH═CR x R x , —CH═CH(CH 2 ) 1-3 CH═CR x R x , —CH═CHR z , —(CH 2 ) 1-3 R z , —(CH 2 ) 1-3 O(CH 2 ) 0-3 R z , —(CH 2 ) 1-3 S(CH 2 ) 0-3 R z , —CH 2 S(O)R z , —CH 2 S(O) 2 R z , —O(CH 2 ) 1-2 R z , —O(CH 2 ) 1-2 O(CH 2 ) 0-2 R z , —OC(O)R z , —(CH 2 ) 1-4 O(CH 2 ) 0-9 C(R x ) 3 , —(CH 2 ) 1-4 O(CH 2 ) 0-9 CF 3 , —(CH 2 ) 1-4 CR x R x O(CH 2 ) 0-4 C(R x ) 3 , —(CH 2 ) 1-3 O(CH 2 ) 1-4 CH═CR x (CH 2 ) 0-3 CH 3 , —(CH 2 ) 1-3 O(CH 2 ) 1-4 CH═CR x R x , —(CH 2 ) 1-3 O(CH 2 ) 1-4 C(OH)R x R x , —(CH 2 ) 1-3 O(CH 2 ) 1-4 O(CH 2 ) 0-3 CH 3 , —(CH 2 ) 1-3 S(CH 2 ) 0-4 C(R x ) 3 , —(CH 2 ) 0-3 O(CH 2 ) 1-4 S(CH 2 ) 0-3 C(R x ) 3 , —(CH 2 ) 1-3 S(CH 2 ) 1-4 Si(CH 3 ) 3 , —(CH 2 ) 1-3 S(O)(CH 2 ) 0-4 C(R x ) 3 , —(CH 2 ) 1-3 S(O) 2 (CH 2 ) 0-4 C(R x ) 3 , —(CH 2 ) 1-5 NR x R x , —O(CH 2 ) 1-7 C(R x ) 3 , —O(CH 2 ) 1-4 O(CH 2 ) 0-4 C(R x ) 3 , —O(CH 2 ) 1-4 CH═CR x (CH 2 ) 0-3 CH 3 , —O(CH 2 ) 1-4 (CH 2 ) 0-3 C(R x ) 3 , —O(CH 2 ) 1-4 O(CH 2 ) 1-3 CH═CR x R x , —O(CH 2 ) 1-4 O(CH 2 ) 1-3 C≡CR x , —C(O)(CH 2 ) 0-4 C(R x ) 3 , —OC(O)(CH 2 ) 0-4 C(R x ) 3 , —OC(O)CR x R x (CH 2 ) 0-4 C(R x ) 3 , —OC(O)NR x (CH 2 ) 0-5 C(R x ) 3 , —NR x C(O)NR x (CH 2 ) 0-5 C(R x ) 3 , —C(CH 3 )═N—O(CH 2 ) 0-5 C(R x ) 3 , —C(CH 3) ═N—O(CH 2 ) 1-2 (phenyl), —C(CH 3 )═N—O(CH 2 ) 1-2 (fluorophenyl), —C(CH 3 )═N—O(CH 2 ) 1-2 (methoxyphenyl), phenyl, or pyridinyl;
R 2b is
(i) a 6-membered spiro-ring having one oxygen atom and substituted with R b , wherein R b is H or —(CH 2 ) 3 CH 3 ; or
(ii) ═N—O—(CH 2 ) 3 CH 3 , ═N—O—CH 2 CH(CH 3 ) 2 , ═N—OCH 2 CH 2 (phenyl), or ═N—O—CH 2 CH 2 CH 2 (phenyl);

R a is H
each R b is H
each R c is H,
each R x is independently H or —CH 3 ; and
R z is phenyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, quinolinyl, thiophenyl, thiazolyl, oxetanyl, C 3-6 cycloalkyl, adamantanyl, or tetrahydropyranyl, each substituted with zero to 4 substituents independently selected from F, Cl, I, C 1-4 alkyl, —O(C 1-3 alkyl), —CF 3 , —OCF 3 , —(CH 2 ) 1-6 OCH 3 , —CH 2 NR x R x , —C(O)NR x R x , —C(O)NR x (C 1-4 alkyl), and —CH 2 C(O)NR x R x ;
with the proviso that R 2 is not —(CH 2 ) 5 CH 3 wherein said autoimmune disease or chronic inflammatory disease is selected from systemic lupus erythematosis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, scleroderma, giant cell arteritis, and Sjögren's syndrome.

2. The method according to claim 1 wherein said compound is

or a salt thereof.

3. The method according to claim 1 wherein said compound is

or a salt thereof.

4. The method according to claim 2 wherein said autoimmune disease or chronic inflammatory disease is systemic lupus erythematosis.

5. The method according to claim 2 wherein said autoimmune disease or chronic inflammatory disease is ulcerative colitis.

6. The method according to claim 2 wherein said autoimmune disease or chronic inflammatory disease is multiple sclerosis.

7. The method according to claim 2 wherein said autoimmune disease or chronic inflammatory disease is inflammatory bowel disease.

8. The method according to claim 2 wherein said autoimmune disease or chronic inflammatory disease is rheumatoid arthritis.

9. The method according to claim 2 wherein said autoimmune disease or chronic inflammatory disease is Crohn's disease.

10. The method according to claim 2 wherein said autoimmune disease or chronic inflammatory disease is Sjögren's syndrome.

11. The method according to claim 3 wherein said autoimmune disease or chronic inflammatory disease is systemic lupus erythematosis.

12. The method according to claim 3 wherein said autoimmune disease or chronic inflammatory disease is ulcerative colitis.

13. The method according to claim 3 wherein said autoimmune disease or chronic inflammatory disease is multiple sclerosis.

14. The method according to claim 3 wherein said autoimmune disease or chronic inflammatory disease is inflammatory bowel disease.

15. The method according to claim 3 wherein said autoimmune disease or chronic inflammatory disease is rheumatoid arthritis.

16. The method according to claim 2 wherein said autoimmune disease or chronic inflammatory disease is Crohn's disease.

17. The method according to claim 2 wherein said autoimmune disease or chronic inflammatory disease is Sjögren's syndrome.

Assignees

• Bristol Myers Squibb Co

Inventors

• Dyckman Alaric J
• Dhar T G Murali
• Xiao Hai-Yun
• Gilmore John L
• Yang Michael G
• Xiao Zili
• Marcoux David

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title